Omole Emmanuel B, Aijaz Iqbal, Ellegate James, Isenhart Emily, Desouki Mohamed M, Mastri Michalis, Humphrey Kristen, Dougherty Emily M, Rosario Spencer R, Nastiuk Kent L, Ohm Joyce E, Eng Kevin H
Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Cancers (Basel). 2022 Sep 28;14(19):4724. doi: 10.3390/cancers14194724.
Like BRCA2, MAGEC3 is an ovarian cancer predisposition gene that has been shown to have prognostic significance in ovarian cancer patients. Despite the clinical significance of each gene, no studies have been conducted to assess the clinical significance of their combined expression. We therefore sought to determine the relationship between MAGEC3 and BRCA2 expression in ovarian cancer and their association with patient characteristics and outcomes. Immunohistochemical staining was quantitated on tumor microarrays of human tumor samples obtained from 357 patients with epithelial ovarian cancer to ascertain BRCA2 expression levels. In conjunction with our previously published MAGEC3 expression data, we observed a weak inverse correlation of MAGEC3 with BRCA2 expression (r = −0.15; p < 0.05) in cases with full-length BRCA2. Patients with optimal cytoreduction, loss of MAGEC3, and detectable BRCA2 expression had better overall (median OS: 127.9 vs. 65.3 months, p = 0.035) and progression-free (median PFS: 85.3 vs. 18.8 months, p = 0.002) survival compared to patients that were BRCA2 expressors with MAGEC3 normal levels. Our results suggest that combined expression of MAGEC3 and BRCA2 serves as a better predictor of prognosis than each marker alone.
与BRCA2一样，MAGEC3是一种卵巢癌易感基因，已被证明在卵巢癌患者中具有预后意义。尽管每个基因都具有临床意义，但尚未进行研究来评估它们联合表达的临床意义。因此，我们试图确定MAGEC3和BRCA2在卵巢癌中的表达关系，以及它们与患者特征和预后的关联。对从357例上皮性卵巢癌患者获得的人类肿瘤样本的肿瘤微阵列进行免疫组织化学染色定量，以确定BRCA2表达水平。结合我们之前发表的MAGEC3表达数据，我们观察到在全长BRCA2的病例中，MAGEC3与BRCA2表达呈弱负相关（r = -0.15；p < 0.05）。与MAGEC3水平正常的BRCA2表达者相比，细胞减灭术最佳、MAGEC3缺失且可检测到BRCA2表达的患者具有更好的总生存期（中位OS：127.9个月对65.3个月，p = 0.035）和无进展生存期（中位PFS：85.3个月对18.8个月，p = 0.002）。我们的结果表明，MAGEC3和BRCA2的联合表达比单独的每个标志物更能预测预后。
